$-0.82 EPS Expected for Caladrius Biosciences, Inc. (CLBS); Magna International Inc. (MGA) Had 9 Bullish Analysts

April 23, 2018 - By Linda Rogers

Magna International Inc. (NYSE:MGA) Logo

Analysts expect Caladrius Biosciences, Inc. (NASDAQ:CLBS) to report $-0.82 EPS on May, 21.They anticipate $0.30 EPS change or 26.79% from last quarter’s $-1.12 EPS. After having $-0.40 EPS previously, Caladrius Biosciences, Inc.’s analysts see 105.00% EPS growth. The stock decreased 0.43% or $0.02 during the last trading session, reaching $4.61. About 17,365 shares traded. Caladrius Biosciences, Inc. (NASDAQ:CLBS) has risen 20.65% since April 23, 2017 and is uptrending. It has outperformed by 9.10% the S&P500.

Among 15 analysts covering Magna International (NYSE:MGA), 9 have Buy rating, 2 Sell and 4 Hold. Therefore 60% are positive. Magna International had 56 analyst reports since August 6, 2015 according to SRatingsIntel. The company was maintained on Friday, July 21 by RBC Capital Markets. TD Securities upgraded the stock to “Buy” rating in Friday, May 12 report. The firm has “Buy” rating by RBC Capital Markets given on Thursday, February 22. RBC Capital Markets maintained the stock with “Buy” rating in Sunday, October 29 report. The firm earned “Overweight” rating on Thursday, March 17 by Morgan Stanley. The company was maintained on Thursday, September 14 by BMO Capital Markets. The firm has “Buy” rating given on Friday, March 16 by Bank of America. The firm earned “Equal-Weight” rating on Monday, August 28 by Morgan Stanley. The stock has “Hold” rating by BMO Capital Markets on Monday, November 6. The firm has “Sell” rating given on Monday, October 16 by Goldman Sachs. See Magna International Inc. (NYSE:MGA) latest ratings:

22/03/2018 Broker: Morgan Stanley Rating: Sell Downgrade
22/03/2018 Broker: Inc. Common Stock Rating: Morgan Stanley
16/03/2018 Broker: Bank of America Rating: Buy New Target: $67.0 Maintain
14/03/2018 Broker: Susquehanna Rating: Hold New Target: $57.0 Maintain
09/03/2018 Broker: Inc. Common Stock Rating: Citigroup New Target: $61 67
09/03/2018 Broker: Citigroup Rating: Buy New Target: $67.0
22/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $71.0 Maintain
23/02/2018 Broker: Inc. Common Stock Rating: Deutsche Bank New Target: $61 68
19/01/2018 Broker: TD Securities Rating: Hold New Target: $65.0 Downgrade
17/01/2018 Broker: RBC Capital Markets Rating: Buy New Target: $70.0 Maintain

The stock increased 1.05% or $0.62 during the last trading session, reaching $59.59. About 609,339 shares traded. Magna International Inc. (NYSE:MGA) has risen 26.62% since April 23, 2017 and is uptrending. It has outperformed by 15.07% the S&P500.

Magna International Inc. designs, develops, and makes automotive systems, assemblies, modules, and components in North America, Europe, Asia, and South America. The company has market cap of $20.55 billion. The firm offers engineering and contract manufacturing services, and fuel systems; electric/electronic components and systems; roof systems comprising softtops, retractable hardtops, modular tops, and hardtops; and closures, including latching systems, hinges and wire forming, power closures, electronics, door modules, window systems engineered glass, sealing, trim and roof racks, roof systems, testing centers, and running boards. It has a 10.1 P/E ratio. It also provides interior and exterior mirrors, actuators, electronic vision systems, door handle and overhead console technologies, and front and signal lightings; complete seating systems, mechanism solutions, seat structure solutions, foam and trim products, and design and development solutions; and fascia and exterior trims, liftgate and exterior modules, front end modules, ACTERO active aerodynamics, and lightweight composites.

Among 4 analysts covering Caladrius Biosciences (NASDAQ:CLBS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Caladrius Biosciences had 15 analyst reports since August 7, 2015 according to SRatingsIntel. On Tuesday, March 6 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was maintained by H.C. Wainwright on Friday, January 19 with “Buy”. On Tuesday, August 23 the stock rating was initiated by Chardan Capital Markets with “Buy”. The rating was downgraded by H.C. Wainwright on Friday, January 8 to “Neutral”. The firm has “” rating given on Friday, August 7 by Benchmark. The firm earned “Buy” rating on Friday, April 29 by H.C. Wainwright. H.C. Wainwright maintained the stock with “Buy” rating in Friday, November 10 report. The stock of Caladrius Biosciences, Inc. (NASDAQ:CLBS) has “Buy” rating given on Tuesday, December 22 by Maxim Group. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, March 14 report. The rating was maintained by Chardan Capital Markets with “Buy” on Friday, March 23.

Caladrius Biosciences, Inc. (NASDAQ:CLBS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Linda Rogers

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts